Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Betrixaban hydrochloride(330942-05-7(free base)) (PRT054021 hydrochloride) 是一种有效的、选择性的、口服有效的 Xa 因子 (fXa) 抑制剂 (IC50: 1.5 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 375 | 待询 | ||
2 mg | ¥ 538 | 待询 | ||
5 mg | ¥ 968 | 待询 | ||
10 mg | ¥ 1,510 | 待询 | ||
25 mg | ¥ 3,430 | 待询 | ||
50 mg | ¥ 4,900 | 待询 | ||
100 mg | ¥ 7,120 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,030 | 待询 |
Betrixaban hydrochloride(330942-05-7(free base)) 的其他形式现货产品:
产品描述 | Betrixaban hydrochloride(330942-05-7(free base)) (PRT054021 hydrochloride) is a potent, selective, and orally efficacious factor Xa (fXa) inhibitor (IC50: 1.5 nM). |
靶点活性 | FXa:1.5 nM |
体外活性 | In patch clamp hERG assays, Betrixaban has IC50 of 8.9 μM. The plasma kallikrein IC50 and Ki values for Betrixaban are 6.3 μM and 3.5 μM respectively. Betrixaban (hERG Ki 1.8 μM) exhibits significantly lower hERG activity than all the others (hERG Ki?0.5 μM)[1]. |
体内活性 | Betrixaban (0.5 mg/kg, i.v. and 2.5 mg/kg, p.o.) has bioavailability of 51.6% in dog; dosed at 0.75 mg/kg IV and 7.5 mg/kg PO, Betrixaban has bioavailability of 58.7% in monkey[1]. Both Betrixaban and Apixa-ban-mediated whole-blood INR increases are similarly reversed by r-Antidote. After i.v. infusion of the three fXa inhibitors (each admin?istered individually) for 30 min, the total plasma concentrations of rivaroxaban, Betrixaban and apixaban are 1.4±0.4 μM (mean±s.d.), 0.2±0.01 μM and 1.4±0.3 μM, respectively, and the percentages of unbound inhibitor are 2.2%±0.8% (mean±s.d.), 40%±7.2% and 1.5%±0.3%, respectively. After administration of r-Antidote, the total plasma concentrations of the inhibitors increased to 1.9±0.09 μM, 2.0±0.4 μM and 4.2±0.7 μM, respectively, and the percentage of unbound inhibitor declined to 0%, 0.3%±0.1% and 0.05%±0.02%, respectively. Thus, for each of the three inhibitors, correction of prothrombin time by r-Antidote to near-normal values is associated with a reduction in the free fraction of the inhibitor[2]. |
别名 | PRT054021 hydrochloride, 盐酸贝曲西班 |
分子量 | 488.36 |
分子式 | C23H23Cl2N5O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL (44.26 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0477 mL | 10.2383 mL | 20.4767 mL | 51.1917 mL |
5 mM | 0.4095 mL | 2.0477 mL | 4.0953 mL | 10.2383 mL | |
10 mM | 0.2048 mL | 1.0238 mL | 2.0477 mL | 5.1192 mL | |
20 mM | 0.1024 mL | 0.5119 mL | 1.0238 mL | 2.5596 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Betrixaban hydrochloride(330942-05-7(free base)) Metabolism Factor Xa PRT054021 hydrochloride Betrixaban hydrochloride(330942057(free base)) PRT054021 Hydrochloride PRT 054021 Hydrochloride PRT-054021 Hydrochloride Betrixaban hydrochloride(330942 05 7(free base)) 盐酸贝曲西班 Inhibitor inhibitor inhibit